Latest news with #LeviKorsinsky
Associated Press
30-05-2025
- Business
- Associated Press
IBTA LAWSUIT ALERT: Levi & Korsinsky Notifies Ibotta, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ibotta investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ibotta securities pursuant and/or traceable to documents issued in connection with Ibotta's April 18, 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team: IBTA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that they did not properly warn investors of the risks concerning Ibotta's contract with The Kroger Co. ('Kroger'). Kroger's contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta's contract with Walmart, there was not a single warning of the at-will nature of Kroger's contract. Rather than disclosing the very real risk of a major client walking away at any time, Ibotta provided boilerplate warnings concerning the importance of maintaining ongoing relationships with their clients. WHAT'S NEXT? If you suffered a loss in Ibotta during the relevant time frame, you have until June 16, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171
Associated Press
30-05-2025
- Business
- Associated Press
Class Action Filed Against West Pharmaceutical Services, Inc. (WST) - July 7, 2025 Deadline to Join – Contact Levi & Korsinsky
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ('West Pharmaceutical Services, Inc.' or the 'Company') (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a member of our team: WST investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with longstanding customers; and (d) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in West Pharmaceutical Services, Inc. during the relevant time frame, you have until July 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171
